Resource Logo
Reuters New Media

Shionogi to take 10 pct stake in GSK, Pfizer HIV drug venture


(Reuters) - Japan's Shionogi & Co (4507.T) said on Monday that it will take a 10 percent stake in Viiv Healthcare, a AIDS drug joint venture between GlaxoSmithKline (GSK.L) and Pfizer (PFE.N), in exchange for its rights to the drug Dolutegravir.

Shionogi, which will retain intellectual property rights to the drug, will gain one Viiv board seat and receive royalties of 15 percent to 19 percent on sales of Dolutegravir and related products, it said in a statement.

Financial terms were not disclosed. After the deal GSK will hold 76.5 percent in the venture, while Pfizer will hold 13.5 percent.

(Reporting by Mayumi Negishi; Editing by Edwina Gibbs)


Copyright © 2012 -Reuters New Media, Publisher. All rights reserved to Reuters .Ltd. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Information in this article was accurate in October 28, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.